The claim: The first night of the Republican National Convention had 128.4 million viewers
As the political conventions wound down, posts circulated stating the viewership of the Republican National Convention simply crushed that of its counterpart, the Democratic National Convention.
“Day 1 DNC : 21.4 Million Viewed. Day 1 RNC : 128.4 Million Views,” a post from the page Absolute Patriot states. Other posts echoed that, with one being shared over 7,000 times (that post has since been deleted).
The RNC was held the week after the DNC.
Fact check: In 2010, Donald Trump offered $6M to try to stop a mosque near Ground Zero
What do the ratings show?
According to the ratings service Nielsen, an estimated 17 million people tuned into the first night of the RNC on TV, while an estimated 19.7 million people watched the first night of the DNC on TV.
While those numbers do not include the total number of people who streamed the conventions, the author of the post provided no source to back up his claim, and USA TODAY could find no evidence supporting it.
It appears the RNC figure may have been determined by starting with the reported initial figure for day three viewership of the DNC — 21.4 million.
After numerous commenters panned the post as inaccurate, the poster linked to a tweet by the founder of a far-right website who noted — accurately, according to multiple news reports — that nearly six times as many people streamed the start of the RNC than the DNC on C-SPAN — 440,000 views to 76,000 views.
If you take 21.4 million and multiply it by six — to mirror that C-SPAN number — you get 128.4 million.
The person who created the deleted post did not respond to a query from USA TODAY about the source for the figure. When challenged numerous times by commenters who linked to the correct figures, he generally responded “fake news.”
USA TODAY has reached out to the Absolute Patriot page for comment.
Fact check: On a viral list of 10 Trump ‘accomplishments,’ 3 are true
Our rating: False
We rate this claim as FALSE, because it is not supported by our research. Data confirms that neither party topped 20 million TV viewers on day one of their respective conventions — a figure over 100 million shy of the figure claimed for the GOP convention. In fact, no TV program has ever hit 128 million viewers nationwide. .
Our fact-check sources:
Nielsen, Aug. 18, Media Advisory: First Night of 2020 Democratic National Convention Draws 19.7 million viewers
Nielsen, Aug. 25, First Night of 2020 Republican National Convention Draws 17 million viewers
TV guide, Aug. 27, RNC vs. DNC Ratings: Kamala Harris Draws 5.7 Million More Viewers Than Mike Pence
The Hill, Aug. 25, First night of GOP convention delivers nearly six times more views than start of Democrats’ event on C-SPAN livestream
NPR, Feb. 2, 2015, Super Bowl XLIX Was Most Watched Show In TV History
Wikipedia, List of most watched television broadcasts in the United States
Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.
Our fact check work is supported in part by a grant from Facebook.
This article originally appeared on USA TODAY: Fact check: RNC’s first night viewership not as high as posts boast
Barstool App Breaks DraftKings Download Record, Analyst Says
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%
Is it time for the bears to break out the champagne glasses? Not so fast, says Goldman Sachs. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs’ head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening. This would reflect gains of 10% and 16%, respectively, should the index ultimately reach these targets.“Despite the sharp sell-off in the past week, we remain optimistic about the path of the U.S. equity market in coming months. The Superforecaster probability of a mass-distributed vaccine by Q1 2021 has surged to nearly 70% and economic data show a continuing recovery,” Kostin wrote in a recent note. On top of this, the strategist argues the vaccine’s arrival will push U.S. GDP growth to 6%, compared to the 3.9% consensus estimate.Given Kostin’s outlook, we wanted to check out three stocks scoring major praise from Goldman Sachs. Not only have they been given a Buy rating, but the firm’s analysts also see at least 50% upside potential on tap for each. Using TipRanks’ database, we found out that all three tickers have gotten a thumbs up from analysts at other firms as well. Let’s take a closer look.Intellia Therapeutics (NTLA)Focused on utilizing gene editing to develop cell therapies, Intellia Therapeutics wants to stomp out cancer and other immunological diseases for good. Based on its innovative technology, Goldman Sachs recommends that investors pull the trigger.Representing the firm, 5-star analyst Salveen Richter believes that what makes NTLA a stand-out is its “use of an adaptive gene editing system based on a proprietary lipid nanoparticle (LNP) delivery method of CRISPR/Cas9 to leverage multiple gene editing strategies.” These include the generation of knock-outs (KO) for toxic genes, restoring functional genes by inserting new DNA sequences and the use of consecutive editing combining KO and insertion approaches.“We are positive on NTLA’s in vivo gene editing approach as it offers a modular system with CRISPR/Cas9 gene editing for functionally curative outcomes. While we note the initial focus is on delivery to the liver, extrahepatic tissue targeting (i.e. CNS) could expand the breadth of NTLA’s platform. NTLA is also leveraging its CRISPR/Cas9 editing tools ex vivo to create next-generation engineered cells that can treat oncological and immunological diseases,” Richter explained.To this end, the analyst sees several potential catalysts on tap for the next year. Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues, could come by mid-2021. This data stands to “inform the drug’s clinical profile (safety/tolerability and early signs of sustained TTR knockdown),” which would de-risk NTLA’s in vivo editing platform, in Richter’s opinion.On top of this, IND-enabling studies for NTLA-2002, its therapy designed for hereditary angioedema (HAE), and NTLA-5001, its therapy for WT1+ acute myeloid leukemia (AML), are set to kick off in 2021. Richter estimates that peak sales for both candidates could reach $895 million and $806 million, respectively, with data from both also validating “the breadth of editing approaches (knockouts and/or insertions).”If that wasn’t enough, Richter cites the ongoing NVS-led Phase 1/2 OTQ923 sickle cell disease (SCD) trial as a possible upside driver. “While we note the limited economics to NTLA from this program and competitor dynamics with bluebird bio’s (BLUE) LentiGlobin and CRISPR Therapeutics’ (CRSP) CTX001 that are ahead in clinical development, the study should serve as proof-of-concept for the platform. First data could be presented in 2021,” the analyst commented.All of this prompted Richer to initiate coverage with a Buy rating and $33 price target. This target conveys her confidence in NTLA’s ability to climb 50% higher in the next year. (To watch Richter’s track record, click here)Looking at the consensus breakdown, 3 Buys and 2 Holds have been published in the last three months. Therefore, NTLA gets a Moderate Buy consensus rating. Based on the $37.13 average price target, shares could rise 67% in the next year. (See NTLA stock analysis on TipRanks)Vir Biotechnology (VIR)Moving on to another healthcare company, Vir Biotechnology is developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in new ways. With it standing at the front of the pack in the COVID-19 monoclonal antibody (mAb) race, it’s no wonder Goldman Sachs likes what it’s seeing.Firm analyst Paul Choi cites a recent data readout from one of VIR’s competitors as reaffirming his confidence. On September 16, Eli Lilly reported interim data from the Phase 2 BLAZE-1 trial evaluating its mAb therapies, LY-CoV555 and LY-CoV016, in mild or moderate COVID-19 patients. The data revealed that treatment with LY-CoV555 led to a roughly 72% reduction in the need for hospitalization, with no safety signals observed.Choi also points out that the results were more “pronounced” in high risk patients (age or BMI) as most study hospitalizations across both groups occurred in patients with these underlying risk factors.While resistant viral variants did appear in 8% of LY-CoV555-treated patients and 6% of patients on placebo, management has stated that competing single or multiple mAb “cocktail” approaches might not be optimized, with viral escape mutants potentially emerging. VIR argues its approach is differentiated given the high barrier to resistance, potent effector function, potential for increased lung tissue concentration and extended half-life.Even though VIR is behind its peers in terms of development timelines, Choi thinks that the company is making substantial progress. VIR recently initiated the Phase 2/3 COMET-ICE study of VIR-7831, its mAb for COVID-19, as a monotherapy (versus a combination approach) in patients with mild or moderate COVID-19. Initial data is set to be released by the end of 2020, with top-line data expected in January. Weighing in on the above, Choi commented, “In the absence of preclinical binding affinity data from LY-CoV555, it is premature to hypothesize on the potential for VIR-7831 to demonstrate improved efficacy vs. the competing antibodies; however, we see the LLY data as establishing proof-of-concept for antibodies in COVID-19 while also setting an attainable bar for future antibody monotherapy/cocktail treatments. Moreover, we view the addressable market for COVID-19 antibodies as significant enough to support several approved therapies in the indication in the near-term.”In line with his optimistic approach, Choi reiterated his Buy rating and $54 price target. Should the 5-star analyst’s thesis play out, a twelve-month gain of 69% could potentially be in the cards. (To watch Choi’s track record, click here)Is the rest of the Street in agreement? The majority of other analysts are. 4 Buys, 1 Hold and 1 Sell have been issued in the last three months, so the word on the Street is that VIR is a Moderate Buy. With the average price target clocking in at $51.67, shares could jump 61% in the next year. (See VIR stock analysis on TipRanks)Peloton Interactive (PTON)Switching gears now, we move on to Peloton Interactive. The company, which offers exercise bikes and remote workout classes, rose to fame at the start of the COVID-19 pandemic. After its fiscal Q4 earnings results blew estimates out of the water, Goldman Sachs believes this stock has more room to run.In the most recent quarter, PTON posted revenue of $607.1 million, beating the $586.2 million consensus estimate and reflecting a 172% year-over-year increase. This is up from growth of 65.6% in the previous quarter. Adjusted EBITDA came in at $143.6 million, ahead of the Street’s $73.5 million call. Management pointed to heightened demand during the COVID-19 crisis and significantly lower marketing spend as the drivers of this strong showing.Goldman Sachs’ Heath Terry tells clients he was especially excited about the Connected Fitness segment’s performance. Connected Fitness product revenue landed at $486 million, up 199% year-over-year, while customer deposits and deferred revenue grew 300% year-over-year. The five-star analyst also highlights the fact that subscriber net adds were 205,000, versus 174,100 net adds in fiscal Q3 2020 and guidance of 154-164,000.As for PTON’s forward-looking guidance, Terry was also impressed. “While the company guided fiscal Q1 2021 and FY21 revenue and adjusted EBITDA well above consensus, given the backlog of demand exiting the June quarter and the 6-8 weeks of deliveries already on order by consumers, we expect this guidance will again prove overly conservative,” he explained.This performance prompted Terry to state, “We continue to believe that Peloton represents a significant long-term opportunity as the company is in the earliest stages of creating new and expanding existing categories of connected fitness products, an opportunity that we believe has been permanently accelerated by the current COVID-19 crisis.”It should be noted that the company faces significant risks going forward. These include new entrants, evolving consumer tastes as well as execution challenges. That being said, Terry’s bullish thesis remains very much intact.Expounding on this, the analyst said, “… we believe that the window of opportunity for any meaningful competitor is rapidly closing, something that, along with the large and expanding addressable market for Peloton’s high ARPU, high margin, extremely low churn subscription business, remains underappreciated by the market, even with the stock’s recent outperformance.”It should come as no surprise, then, that Terry stayed with the bulls. To this end, he kept a Buy rating and $138 price target on the stock. Investors could be pocketing a gain of 53%, should this target be met in the twelve months ahead. (To watch Terry’s track record, click here)In general, other analysts are on the same page. PTON’s Strong Buy consensus rating breaks down into 20 Buys, 2 Holds and 1 Sell. The $112.05 average price target brings the upside potential to 23%. (See PTON stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
XRHealth debuts at-home VR therapy app for ADHD
Attention deficit hyperactivity disorder (ADHD) affects millions of people — over 6 million children in the U.S. alone — and can range from a lack of control over impulsive behavior to an inability to sit still and pay attention. While prescription medications can help with focus, individuals may be able to learn concentration skills through personalized instruction, and XRHealth has developed a VR therapy app that can be used at home for that purpose.
Based on research into brain plasticity — the mind’s ability to restructure itself to overcome challenges — XRHealth’s app presents a visual, auditory, and physical experience that mimics real life, enabling users with ADHD to improve both cognitive abilities and motor movement. As an alternative to game-based ADHD treatments, the VR solution helps users improve their attentiveness, reduce impulsivity, and develop strategic life skills such as planning and executing daily tasks. At the same time, the system measures sustained focus in the presence of distractions.
The COVID-19 pandemic has reduced clinicians’ ability to offer supervised outpatient treatments for ADHD, a condition that affects some business executives, employees, and children who are now studying at home under their parents’ tutelage. Consequently, home therapeutic solutions that can be used without visiting a doctor’s office have become increasingly appealing. The U.S. Food and Drug Administration will allow XRHealth’s app to be used in homes as an adjunct to other treatments, including medication and/or in-person therapy. But there are caveats: The app isn’t intended to replace other treatments, and will require an XRHealth-approved clinician’s guidance. For the time being, it will only be available to users aged 12 and up, as the FDA mulls a possible expansion to users as young as 8 years of age.
Critically, clinicians can use the app to gather eye-tracking data, gaining “unbiased, objective, and quantifiable” information about what the wearer is looking at during each VR session, with the ability to adjust task difficulty to motivate users to continue. Doctors can also see how each user is performing generally on tasks and track session-to-session improvements over time.
Though ADHD is often thought of as a condition affecting children, with serious negative impacts on early reading, writing, math, and scholastic/social interactions, it can persist into adulthood, stifling higher education and work. Some adults with undiagnosed or untreated ADHD are unable to concentrate on tasks for more than brief periods of time before shifting to other subjects, sometimes abandoning tasks without completing them. ADHD medications tend to work for several-hour stretches, but they aren’t an ideal long-term solution.
VR has been gaining steam as a treatment for various medical challenges, ranging from mid-procedure surgical pain to social anxiety, loneliness and isolation. It’s also being used to train doctors and coronavirus frontline workers, as clinicians have seen quantifiable improvements in everything from information retention to user relaxation when consuming VR content.
Pricing and hardware requirements have not yet been announced, but an XRHealth-provided VR Telehealth Kit — including a headset with eye-tracking capabilities, such as Pico’s Neo 2 Eye — will likely be needed for the app to operate at its full potential. XRHealth has offered Oculus Go and Quest-compatible solutions since its earlier days as VRHealth, as well as supporting HTC headsets, and was previously announced as a medical AR partner for Magic Leap.
TikTok writes to rivals over suicide clips
TikTok has written to social media firms asking them to join together to remove content that depicts self-harm or suicide more quickly.
It comes after a clip of a man killing himself was widely circulated on its platform and viewed by young children.
Theo Bertram, Europe’s public policy head, said the sharing of the video suggested a co-ordinated attack, possibly from bot accounts.
He declined to discuss ongoing negotiations on the future of TikTok.
Mr Bertram was being grilled by MPs on the Department of Digital Culture, Media and Sport who are investigating how social media platforms deal with online harms.
They were also keen to hear more about the future of the company outside China, in wake of President Donald Trump’s threat to ban the app in the US unless a deal is struck with American firms.
Owner ByteDance is currently in talks with Oracle and Walmart over its future, but reports suggest that China is unlikely to approve what it sees as an unfair deal.
Mr Bertram said he was not able to comment on the details of the ongoing negotiations.
“I think there are broader concerns around China and China’s role in the world. And I think that these concerns are projected on to TikTok and don’t think they are always fairly projected,” he told MPs.
When pressed on how the platform dealt with content sensitive to the Chinese government, such as protests in Hong Kong and the treatment of the Uighur Muslims, he told MPs: “TikTok is a business outside of China and is led by European management that have the same concerns and the same world view that you do and we care about our users.”
Some of those users have recently been traumatised by a clip circulating on the platform showing a US man killing himself, and Mr Bertram acknowledged that the firm had to “do better”.
Mr Bertram explained that the firm had seen a huge spike in the sharing of the clip a week after the broadcast took place on Facebook Live.
“Following an internal review, we found evidence of a co-ordinated effort by bad actors to spread this video across the internet and platforms, including TikTok.
“And we saw people searching for content in a very specific way. Frequently clicking on a profile of people as if they’re kind of anticipating that those people had uploaded a video.”
He said the firm had written to the chief executives of Facebook, Instagram, Google, YouTube, Twitter, Twitch, Snapchat, Pinterest and Reddit.
“What we are proposing is that, the same way these companies already work together around child sexual imagery and terrorist-related content, we should now establish a partnership around dealing with this type of content.”
And for TikTok itself, he promised “changes to machines learning and emergency systems” as well as how algorithms that detect such content can work better with the firm’s content moderators.
He was also asked about reports that TikTok had removed content around disabilities or LGBTQ.
He explained that “unfortunately” there had been a policy around not promoting content that might encourage bullying, which limited content from people with disabilities and LGBTQ content.
“That is no longer our policy,” he said.
He was less clear on whether the firm restricted the promotion of LGBTQ hashtags in Russia, saying: “Not as far as I’m aware… The only time we will remove that content is when we have a legal requirement to do so.”
- Barstool App Breaks DraftKings Download Record, Analyst Says
- XRHealth debuts at-home VR therapy app for ADHD
- Samsung’s fast, PCIe 4.0-ready 980 Pro SSD can future-proof your PC build
- Saquon Barkley’s big Instagram statement draws NFL stars’ support
- Jabra will add ANC to its Elite 75t earbuds in October
- $20,000 acrylic case installed around Jefferson marker
- Players see similarities between Brad Stevens, Erik Spoelstra
- TikTok writes to rivals over suicide clips
- Curaleaf’s Select Brand Expands Into New York
- Google’s Area 120 launches Tables, a rules-based automation platform for documents
Entertainment3 days ago
Danish TV show ‘Ultra Strips Down’ records kids eyeing naked adults
Sports News3 weeks ago
Fantasy Football Auction Draft strategy: Tips, advice for spending your 2020 player budget wisely
Sports News2 weeks ago
NBA 2K21 Cover Star Damian Lillard Reveals His Issues With the Game
Sports News2 weeks ago
NBA playoff bracket 2020: Updated standings, seeds & results from each round
Sports News2 weeks ago
NFL Analyst Takes a Cheeky Dig on Browns Stars Odell Beckham Jr. and Baker Mayfield
General Other1 week ago
All This Intense Interest in Marathon Oil Stock Is Just Another Fad
Sports3 days ago
What just happened? Danny Lee six-putts 18th green, withdraws from U.S. Open
Tech4 days ago
Destiny 2 Xur location and items, Sept. 18-22